Rugby players from Gloucester and Hartpury are to take part in a major study led by the University of Birmingham as part of its work to develop a ground-breaking pitch-side test to diagnose concussion and brain injury.

The study, being carried out in collaboration with the Rugby Football Union (RFU), Premiership Rugby and the Rugby Players’ Association, will involve all clubs in the Aviva Premiership Rugby and Greene King IPA Championship and will run throughout the 2017/18 rugby season. It is the biggest of its kind to take place in the history of UK sport.

It is a key element in the University of Birmingham’s research programme to create a test that can be performed rapidly pitch-side and will determine whether a player has been concussed. The study is part of the University of Birmingham’s Repetitive Concussion in Sport (RECOS) project.

The test also has the potential to assist in return-to-play decisions and could be used across sports from grassroots to professional level.

It is hoped it could also be used more widely by frontline medics in the NHS and military to improve diagnosis and treatment within the first critical hour after brain trauma.

The team at the University’s College of Medical and Dental Sciences, led by neurosurgeon Professor Tony Belli, has spent the last nine years carrying out research which has led to the development of a test that measures biomarkers present in the saliva and urine of players. The test, if validated, could be done on a hand-held device, which is currently under development.

Professor Belli said: “Early and accurate diagnosis of concussion is one of the biggest challenges we face clinically and is particularly a major concern in the sporting world.

“The University of Birmingham recently made a significant breakthrough after identifying molecules, which can be found in saliva and act as biomarkers to indicate whether the brain has suffered injury.

“In this exciting next study with the RFU, Premiership Rugby and the RPA, we will collect players’ saliva and urine pre and post-injury, which we will then test in the laboratory in order to assess the reliability of these biomarkers.

“If these biomarkers are found reliable, we can continue our work with industrial partners with the hope to have a device available within the next two years that will instantaneously diagnose concussion on the pitch-side with the same accuracy as in the laboratory – a major step forward for both sport and medicine.”

Dr Simon Kemp, RFU Chief Medical Officer, explained: “This is an important addition to the breadth of research we are undertaking into concussion and player welfare more broadly. There is currently no reliable or proven biomarker or objective test for the diagnosis of concussion and this lack of objectivity is the biggest challenge facing medical professionals in dealing with this type of injury.

“While very much an exploratory piece of research, this is a project that has the potential to make a very significant impact on the diagnosis and management of players following concussion.”